Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Zai Lab Ltd ( (HK:9688) ) is now available.
Zai Lab Limited announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan. On September 8, 2025, the company granted options to subscribe for 6,600 American Depositary Shares (ADSs) to two employees and 9,893 restricted share units to four employees. These grants are part of the company’s strategy to align employee incentives with its long-term goals, although they do not include performance targets or clawback mechanisms. The move is seen as market competitive and consistent with the company’s customary practices.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company operates in the healthcare industry, primarily targeting the treatment of cancer, autoimmune, and infectious diseases.
Average Trading Volume: 17,515,161
Technical Sentiment Signal: Sell
Current Market Cap: HK$26.97B
See more insights into 9688 stock on TipRanks’ Stock Analysis page.